| Title |
Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder
|
|---|---|
| Published in |
Psychiatry Research, April 2017
|
| DOI | 10.1016/j.psychres.2017.04.025 |
| Pubmed ID | |
| Authors |
Jeesun Jung, Elisabeth A. Tawa, Christine Muench, Allison D. Rosen, Karl Rickels, Falk W. Lohoff |
| Abstract |
We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina PsychChip, and 266,820 common single nucleotide polymorphisms (SNPs) were analyzed. Although no SNPs reached genome-wide significance, 8 SNPs were marginally associated with treatment response/remission and HAM-A reduction at week 12 and 24 (p<0.00001). Several identified genes may indicate markers crossing neuropsychiatric diagnostic categories. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 13% |
| Student > Bachelor | 4 | 13% |
| Researcher | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Doctoral Student | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 12 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 6 | 19% |
| Medicine and Dentistry | 4 | 13% |
| Neuroscience | 3 | 9% |
| Immunology and Microbiology | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 13 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 May 2017.
All research outputs
#19,951,180
of 25,382,440 outputs
Outputs from Psychiatry Research
#5,570
of 7,588 outputs
Outputs of similar age
#233,872
of 323,237 outputs
Outputs of similar age from Psychiatry Research
#89
of 137 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,588 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,237 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.